Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17674506 | 0.98 | ARG1 (0.33) | ARG1ARG2CYP2C19 | |
| SCHEMBL19308 | 0.93 | — | — | |
| SCHEMBL2183127 | 0.93 | — | — | |
| SCHEMBL313044 | 0.93 | — | — | |
| Water SCHEMBL28255872 | 0.91 | ARG1 (0.37) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL3662817 | 0.91 | ARG1 (0.37) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL7981515 | 0.91 | ARG1 (0.37) | ARG1ARG2 | |
| Iodide SCHEMBL28627113 | 0.88 | ARG1 (0.36) | ARG1ARG2 | |
| Ethylenediamine SCHEMBL27480765 | 0.83 | ARG1 (0.37) | ARG1ARG2 | |
| SCHEMBL18121150 | 0.79 | PARP1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100698-A1 | L-GLUTAMATE OXIDASE, AND METHOD FOR PRODUCING α-KETOGLUTARIC ACID OR HYDROXYPIPECOLIC ACID | ＵＢＥ株式会社 | 2026-05-15 | — | — | WO | claimed |
| EP-4649157-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | Mojia Biotech Pte. Ltd. (SG) | 2025-11-19 | — | — | EP | claimed |
| US-12173330-B2 | Method for producing hydroxy-L-pipecolic acid | API CORPORATION (JP) | 2024-12-24 | — | — | US | claimed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | claimed |
| US-20230265475-A1 | METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | API CORPORATION (JP) | 2023-08-24 | — | — | US | claimed |
| CN-116396991-A | Process for producing hydroxy-L-pipecolic acid | 株式会社API | 2023-07-07 | — | — | CN | claimed |
| US-11591577-B2 | Method for producing hydroxy-L-pipecolic acid | API CORPORATION (JP) | 2023-02-28 | — | — | US | claimed |
| CN-107532185-B | Process for producing hydroxy-L-pipecolic acid | 株式会社API | 2023-01-06 | — | — | CN | claimed |
| US-20210180097-A1 | METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | API CORPORATION (JP) | 2021-06-17 | — | — | US | claimed |
| US-10954539-B2 | Method for producing hydroxy-L-pipecolic acid | API CORPORATION (JP) | 2021-03-23 | — | — | US | claimed |
| US-20180273993-A1 | METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | API CORPORATION (JP) | 2018-09-27 | — | — | US | claimed |
| EP-3358016-A1 | METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | API Corporation (JP) | 2018-08-08 | — | — | EP | claimed |
| EP-2889378-B1 | METHOD FOR PRODUCING HYDROXY-L-LYSINE EMPLOYING AN L-LYSINE HYDROXYLASE AND METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | API CORP (JP) | 2018-01-10 | — | — | EP | claimed |
| WO-2017213758-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | CODEXIS, INC. (US) | 2017-12-14 | — | — | WO | claimed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | claimed |
| US-9512452-B2 | L-lysine hydroxylase and production method for hydroxy-L-lysine and hydroxy-L-pipecolic acid using same | API CORPORATION (JP) | 2016-12-06 | — | — | US | claimed |
| US-20160286791-A1 | BACTERICIDAL COMPOSITIONS AND METHODS FOR TREATING PATHOGENIC BIOFILMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION | 2016-10-06 | — | — | US | claimed |
| US-20150259715-A1 | L-Lysine Hydroxylase and Production Method for Hydroxy-L-Lysine and Hydroxy-L-Pipecolic Acid Using Same | API CORPORATION (JP) | 2015-09-17 | — | — | US | claimed |
| EP-2889378-A1 | PRODUCTION METHOD FOR L-LYSINE HYDROXYLASE AND HYDROXY-L-LYSINE USING SAME, AND PRODUCTION METHOD FOR HYDROXY-L-PIPECOLIC ACID | API Corporation (JP) | 2015-07-01 | — | — | EP | claimed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | ARG1 610/4885ARG2 125/4885CYP2C19 2634/4885 |
| US-20160286791-A1 | BACTERICIDAL COMPOSITIONS AND METHODS FOR TREATING PATHOGENIC BIOFILMS | SERPINB1, CFTR, CLPP | ARG1 544/4885ARG2 2104/4885CYP2C19 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.